CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12345678910111213...39313932»
  • ||||||||||  Monjuvi (tafasitamab-cxix) / Incyte
    Journal:  Sakemura RL, Manriquez Roman C, Horvei P, et (Pubmed Central) -  Oct 3, 2024   
    These HRQoL results together with published reports of efficacy, support the use of pembrolizumab plus chemotherapy as first-line therapy for advanced/metastatic esophageal cancer. No abstract available
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer
    Journal:  Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. (Pubmed Central) -  Oct 3, 2024   
    The degrader can effectively inhibit ROS1-dependent cell proliferation and tumor growth by degrading the ROS1 kinase, thereby eliminating the active phospho-ROS1. More importantly, the degradation-based therapeutic modality can overcome on-target mutation resistance to tyrosine kinase inhibitors by efficient degradation of the mutated kinase to achieve greater potency than inhibition.
  • ||||||||||  tofacitinib / Generic mfg.
    Journal, HEOR:  Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis. (Pubmed Central) -  Oct 3, 2024   
    This study aimed to evaluate the cost-effectiveness of introducing tofacitinib in second-line therapies after methotrexate failure for rheumatoid arthritis in France...The reference strategy included the four classes of biologics commonly used in France (TNFi, tocilizumab, abatacept, rituximab)...Our analysis is limited to severe adverse effects, and their cost is extrapolated from the average hospitalisation cost. The estimated costs are therefore underestimated for chronic diseases such as cancer.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal:  Clinical utility of salivary and lacrimal gland ultrasonography in primary Sj (Pubmed Central) -  Oct 3, 2024   
    A better treatment response to rituximab and salivary stimulants was observed in SjS patients with lower SGUS scores...Ultrasonography has great advantages such as immediate performance and interpretation, no harmful complications, and no discomfort to patients. Therefore, SGUS and LGUS are potentially useful diagnostic and predictive tools for SjS.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    FDA event, Journal:  'Tarlatamab's FDA approval: shaping the future of cancer therapy'. (Pubmed Central) -  Oct 3, 2024   
    This report underscores the importance of extended monitoring, recognizing the potential for late-onset toxicities associated with ICIs, and differentiating from PD-related diarrhea. No abstract available
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  A case report navigating CVID and sarcoidosis overlaps in pediatric nephritis. (Pubmed Central) -  Oct 3, 2024   
    Hypercalcemia and hyperuricemia were managed with fluid resuscitation, calcitonin, and zoledronic acid...Treatment with 60?mg of prednisone began for presumed sarcoidosis for 4?months, causing steroid-induced hypertension and mood changes...He was treated with four cycles of rituximab and granulocyte-colony stimulating factor for persistent neutropenia...The rare complication of granulomatous interstitial nephritis in CVID illustrates the intricate nature of diagnosis. This case underscores the necessity for a holistic view of the patient's clinical and immune phenotype, including distinctive radiological presentations, for precise diagnoses and tailored management of CVID.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    Journal:  Crinkle-Cut Coronary Arteries in a Patient With Granulomatosis With Polyangiitis. (Pubmed Central) -  Oct 3, 2024   
    Cardiac involvement in GPA is often subclinical and if clinically significant has been rarely reported, even less so as an initial presentation. We describe the case of a 44-year-old man who presented with what appeared to be inferior ST-segment elevation myocardial infarction and was found to have small vessel vasculitis of the coronary arteries with associated myocarditis as a presenting manifestation of GPA, which was ultimately treated with steroids, rituximab, and avacopan.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Xolair (omalizumab) / Roche, Novartis, Rituxan (rituximab) / Roche
    Review, Journal:  Updates on the Management of Autoimmune Bullous Diseases. (Pubmed Central) -  Oct 3, 2024   
    The role of biologics and novel therapies like rituximab, omalizumab, and dupilumab in reshaping the management of BP is also discussed. The article highlights the need for further research, clinical trials, and comparative studies to determine the most effective and safest treatment options for patients with immunobullous diseases.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Journal:  Subcellular expression of CD30 in cutaneous mastocytosis-An important factor for targeted treatment. (Pubmed Central) -  Oct 3, 2024   
    Consideration of BM and PD-L1 status in treatment decisions for mUC patients receiving ICIs may improve clinical outcomes. Most cases of cutaneous mastocytosis show cell surface expression of CD30 expression and is, therefore, in principle, accessible for therapy with antibodies against CD30, provided the overall situation of the patient warrants.
  • ||||||||||  Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Journal:  Enfortumab vedotin-induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature. (Pubmed Central) -  Oct 3, 2024   
    An emerging literature of small series and case reports, largely from oncologic literature, presents the histopathology of EV-induced cutaneous eruption as a vacuolar interface dermatitis with the inconsistently reported feature of arrested mitotic figures. This case study demonstrates distinctive clinical and histopathologic features of EV-induced eruption, which may inform dermatologic and oncologic management.
  • ||||||||||  VTP-300 / Vaccitech
    Enrollment closed, Phase classification, Trial completion date, Trial primary completion date:  Efficacy of VTP-300 in Chronic Hepatitis B Infection (clinicaltrials.gov) -  Oct 3, 2024   
    P2,  N=120, Active, not recruiting, 
    Trial completion date: Apr 2025 --> Nov 2024 Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | Trial completion date: Aug 2024 --> Oct 2026 | Trial primary completion date: May 2024 --> Feb 2025
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi (clinicaltrials.gov) -  Oct 3, 2024   
    P2,  N=15, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | Trial completion date: Aug 2024 --> Oct 2026 | Trial primary completion date: May 2024 --> Feb 2025 Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  palazestrant (OP-1250) / Olema Pharma
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus (clinicaltrials.gov) -  Oct 2, 2024   
    P1,  N=155, Recruiting, 
    Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Aug 2025 N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026
  • ||||||||||  SL-172154 / Shattuck
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) -  Oct 2, 2024   
    P1,  N=160, Active, not recruiting, 
    N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026 Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
  • ||||||||||  Trial completion date, Trial suspension, Trial primary completion date:  EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) -  Oct 2, 2024   
    P1/2,  N=18, Suspended, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024 Trial completion date: Jan 2024 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Review, Journal, Checkpoint inhibition:  Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients. (Pubmed Central) -  Oct 2, 2024   
    ICI therapy may lead to cranial nerve involvement, particularly affecting the facial nerve, typically presenting around 10 weeks after treatment initiation. While corticosteroid therapy often resulted in patient improvement, rechallenging with ICIs were associated with new irAEs.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report. (Pubmed Central) -  Oct 2, 2024   
    This unique case report links three important neuroimmunological entities in characterizing the evolution from infectious to autoimmune encephalitis to multiple sclerosis in one patient. Identification of such rare clinical constellations is critical for correct treatment choice and provides important novel insights into the pathophysiology of neuroimmunological disorders including viral triggers and overlap manifestations of autoimmune CNS diseases.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche
    Review, Journal, IO biomarker:  MS treatment de-escalation: review and commentary. (Pubmed Central) -  Oct 2, 2024   
    Extended interval dosing of ocrelizumab mitigated the decline of Ig levels...However, despite several small studies, a definite conclusion about treatment de-escalation in older pwMS will require larger and longer studies. Ideally, comparison of de-escalation versus continuation versus discontinuation of DMTs should be done by prospective randomized-controlled trials enrolling sufficient numbers of subjects to allow comparisons for MS patients of both sexes within age groups, such as 55-59, 60-65, 66-69, etc. Optimally, such studies should be 3
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Metastases:  A case report of metastatic gastric cancer treated with pembrolizumab during pregnancy. (Pubmed Central) -  Oct 2, 2024   
    Ideally, comparison of de-escalation versus continuation versus discontinuation of DMTs should be done by prospective randomized-controlled trials enrolling sufficient numbers of subjects to allow comparisons for MS patients of both sexes within age groups, such as 55-59, 60-65, 66-69, etc. Optimally, such studies should be 3 To the best of our knowledge, this might constitute a possible case of a fetal immune-related adverse event after immunotherapy in utero exposure.